Teva announced the availability of ProAir HFA (albuterol sulfate inhalation aerosol) with a dose counter for use in patients >4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB).
ProAir HFA with a dose counter was approved by the FDA on March 7, 2012. The availability of ProAir HFA with a dose counter supports the FDA’s recommendations for these mechanisms. Patients and caregivers are now able to track the number of doses remaining, which helps reduce the risk of utilizing an inhaler that no longer contains the medication required. Teva has fully converted its supply of ProAir HFA to include the dose counter.
For more information call (888) 838-2872 or visit www.proairhfa.com.